Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immuneering Corp Cl A
(NQ:
IMRX
)
1.640
+0.080 (+5.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immuneering Corp Cl A
< Previous
1
2
Next >
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
April 09, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
March 27, 2024
From
Immuneering Corporation
Via
GlobeNewswire
3 Stocks Insiders Are Buying That Analysts Love
March 26, 2024
Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits.
Via
MarketBeat
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
March 19, 2024
Via
AB Newswire
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
March 14, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
March 12, 2024
Former Chairman, CEO and Founder of ChemoCentryx, Inc.
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
March 11, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
March 06, 2024
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END
Via
FinancialNewsMedia
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
March 05, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
March 04, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 01, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
February 20, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Participation in February Investor Conferences
February 01, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
December 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
October 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the Morgan Stanley Healthcare Conference
September 06, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
June 05, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the Jefferies Healthcare Conference
May 30, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces $30 Million Underwritten Offering
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
April 05, 2023
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 -
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
March 28, 2023
Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
March 14, 2023
From
Immuneering Corporation
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.